Insider Selling: Exelixis, Inc. (NASDAQ:EXEL) EVP Sells $36,486.80 in Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 1,162 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the transaction, the executive vice president now directly owns 498,945 shares in the company, valued at $15,666,873. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Dana Aftab also recently made the following trade(s):

• On Monday, August 12th, Dana Aftab sold 20,883 shares of Exelixis stock. The shares were sold at an average price of $27.06, for a total transaction of $565,093.98.
• On Wednesday, August 7th, Dana Aftab sold 95,000 shares of Exelixis stock. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $34.12 on Monday. Exelixis, Inc. has a 1-year low of $19.20 and a 1-year high of $34.45. The stock has a market cap of $9.74 billion, a P/E ratio of 21.87, a P/E/G ratio of 0.89 and a beta of 0.51. The firm has a fifty day moving average price of $27.13 and a 200 day moving average price of $24.30.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. The business had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 earnings per share. Sell-side analysts expect that Exelixis, Inc. will post 1.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Covestor Ltd lifted its holdings in shares of Exelixis by 5.7% during the third quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 341 shares during the period. CWA Asset Management Group LLC purchased a new stake in shares of Exelixis in the third quarter valued at about $577,000. Capital Performance Advisors LLP acquired a new position in shares of Exelixis during the third quarter worth about $61,000. Heritage Investors Management Corp purchased a new position in Exelixis during the third quarter worth about $201,000. Finally, Capital Management Corp VA lifted its position in Exelixis by 7.5% in the third quarter. Capital Management Corp VA now owns 365,270 shares of the biotechnology company’s stock valued at $9,479,000 after purchasing an additional 25,350 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on EXEL. Piper Sandler upped their price objective on Exelixis from $33.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. TD Cowen lifted their price objective on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Truist Financial boosted their price target on shares of Exelixis from $33.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Guggenheim raised their price objective on shares of Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.44.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.